Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial

[1]  Ewout W Steyerberg,et al.  Predicting outcome after traumatic brain injury: development and validation of a prognostic score based on admission characteristics. , 2005, Journal of neurotrauma.

[2]  Barbara Gregson,et al.  Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. , 2005, Journal of neurotrauma.

[3]  H. Bramlett,et al.  Pathophysiology of Cerebral Ischemia and Brain Trauma: Similarities and Differences , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  W. Hauser,et al.  The Epidemiology of Traumatic Brain Injury: A Review , 2003, Epilepsia.

[5]  N. Knoller,et al.  Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. , 2002, Critical care medicine.

[6]  Peter J. Kirkpatrick,et al.  Head trauma: basic, preclinical, and clinical directions , 2002 .

[7]  H S Levin,et al.  Lack of effect of induction of hypothermia after acute brain injury. , 2001, The New England journal of medicine.

[8]  J. Ghajar.  Traumatic brain injury , 2000, The Lancet.

[9]  R Wentz,et al.  Size and quality of randomised controlled trials in head injury: review of published studies , 2000, BMJ : British Medical Journal.

[10]  Sean M. Grady,et al.  Clinical trials in head injury. , 1999, Journal of neurotrauma.

[11]  E. Steyerberg,et al.  Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations , 1999, Neurosurgery.

[12]  N. Juul,et al.  Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial. , 1998, Neurosurgery.

[13]  G. Teasdale,et al.  Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. , 1998, Journal of neurotrauma.

[14]  M. Dijkers.  Measuring the Long-Term Outcomes of Traumatic Brain Injury: A Review of the Community Integration Questionnaire , 1997 .

[15]  A. Biegon,et al.  Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. , 1997, The Journal of pharmacology and experimental therapeutics.

[16]  M. Brewster,et al.  Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. , 1997, International journal of clinical pharmacology and therapeutics.

[17]  J. Whitehead,et al.  Sample size review in a head injury trial with ordered categorical responses. , 1997, Statistics in medicine.

[18]  M. Dearden,et al.  EBIC-Guidelines for management of severe head injury in adults , 1997, Acta Neurochirurgica.

[19]  T. Ben-Hur,et al.  Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant , 1997, Journal of Neuroimmunology.

[20]  Mark L. Greenberg,et al.  Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Biegon,et al.  Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. , 1995, European journal of pharmacology.

[22]  E. Shohami,et al.  Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat , 1995, Brain Research.

[23]  Anthony Marmarou,et al.  A new classification of head injury based on computerized tomography , 1991 .

[24]  Sung C. Choi,et al.  NINDS Traumatic Coma Data Bank: intracranial pressure monitoring methodology , 1991 .

[25]  Y. Kloog,et al.  Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. M. Toole,et al.  ABSENT OR COMPRESSED BASAL CISTERNS ON FIRST CT SCAN: OMINOUS PREDICTORS OF OUTCOME IN SEVERE HEAD INJURY , 1984, Journal of neurosurgery.

[27]  J. Evans,et al.  Adverse reactions to intravenous anaesthetic induction agents. , 1977, British medical journal.

[28]  E. Steyerberg,et al.  Clinical trials in traumatic brain injury: current problems and future solutions. , 2004, Acta neurochirurgica. Supplement.

[29]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[30]  B. Walters,et al.  Part 1: Guidelines for the management of severe traumatic brain injury , 2000 .

[31]  M. Wahl,et al.  Regulation of cerebral blood flow--a brief review. , 1993, Acta neurochirurgica. Supplementum.

[32]  D. Wade,et al.  The Barthel ADL Index: a reliability study. , 1988, International disability studies.

[33]  B. Günther,et al.  RELATION BETWEEN BODY WEIGHT AND CAFFEINE TOXICITY IN BUFO ARENARUM HENSEL , 1945 .